Is CTOR or ACIU more profitable?

Citius Oncology has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Citius Oncology's return on equity of -99.47% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% AC Immune -1,788.02% -125.26% -40.85%

Does the media prefer CTOR or ACIU?

In the previous week, AC Immune had 3 more articles in the media than Citius Oncology. MarketBeat recorded 5 mentions for AC Immune and 2 mentions for Citius Oncology. AC Immune's average media sentiment score of 0.79 beat Citius Oncology's score of 0.37 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AC Immune 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CTOR or ARTV?

Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Artiva Biotherapeutics N/A N/A -$83.86M -$3.54 N/A

Is CTOR or ARTV more profitable?

Artiva Biotherapeutics' return on equity of -73.15% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Artiva Biotherapeutics N/A -73.15% -62.74%

Does the media prefer CTOR or ARTV?

In the previous week, Artiva Biotherapeutics had 6 more articles in the media than Citius Oncology. MarketBeat recorded 8 mentions for Artiva Biotherapeutics and 2 mentions for Citius Oncology. Artiva Biotherapeutics' average media sentiment score of 1.44 beat Citius Oncology's score of 0.37 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Artiva Biotherapeutics 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IKT or CTOR more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Citius Oncology N/A -99.47% -42.16%

Does the media favor IKT or CTOR?

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 2 articles in the media. Citius Oncology's average media sentiment score of 0.37 beat Inhibikase Therapeutics' score of 0.30 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, AVXL or CTOR?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is AVXL or CTOR more profitable?

Anavex Life Sciences' return on equity of -38.76% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -38.76% -35.01% Citius Oncology N/A -99.47% -42.16%

Does the media favor AVXL or CTOR?

In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 2 articles in the media. Citius Oncology's average media sentiment score of 0.37 beat Anavex Life Sciences' score of 0.34 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor FHTX or CTOR?

In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 2 articles in the media. Citius Oncology's average media sentiment score of 0.37 beat Foghorn Therapeutics' score of 0.33 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Citius Oncology (CTOR) Competitors

$0.68 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.69 +0.01 (+1.41%)

As of 07/2/2026 04:10 PM Eastern

Compare

CTOR vs. ACIU, ARTV, IKT, AVXL, and FHTX

Should you buy Citius Oncology stock or one of its competitors? MarketBeat compares Citius Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Citius Oncology include AC Immune (ACIU), Artiva Biotherapeutics (ARTV), Inhibikase Therapeutics (IKT), Anavex Life Sciences (AVXL), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry.

How does Citius Oncology compare to AC Immune?

Citius Oncology (NASDAQ:CTOR) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Citius Oncology has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
AC Immune	$3.70M	69.00	-$85.03M	-$0.82	N/A

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Citius Oncology presently has a consensus target price of $6.00, suggesting a potential upside of 781.83%. AC Immune has a consensus target price of $7.50, suggesting a potential upside of 198.80%. Given Citius Oncology's higher probable upside, equities analysts plainly believe Citius Oncology is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Citius Oncology has a beta of 3.47, suggesting that its share price is 247% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

In the previous week, AC Immune had 3 more articles in the media than Citius Oncology. MarketBeat recorded 5 mentions for AC Immune and 2 mentions for Citius Oncology. AC Immune's average media sentiment score of 0.79 beat Citius Oncology's score of 0.37 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Citius Oncology has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. Citius Oncology's return on equity of -99.47% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
AC Immune	-1,788.02%	-125.26%	-40.85%

Summary

Citius Oncology beats AC Immune on 9 of the 15 factors compared between the two stocks.

How does Citius Oncology compare to Artiva Biotherapeutics?

Citius Oncology (NASDAQ:CTOR) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Citius Oncology has a beta of 3.47, indicating that its stock price is 247% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Artiva Biotherapeutics	N/A	N/A	-$83.86M	-$3.54	N/A

Artiva Biotherapeutics' return on equity of -73.15% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Artiva Biotherapeutics	N/A	-73.15%	-62.74%

70.5% of Citius Oncology shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Citius Oncology currently has a consensus price target of $6.00, indicating a potential upside of 781.83%. Artiva Biotherapeutics has a consensus price target of $39.00, indicating a potential upside of 305.83%. Given Citius Oncology's higher probable upside, research analysts plainly believe Citius Oncology is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Artiva Biotherapeutics had 6 more articles in the media than Citius Oncology. MarketBeat recorded 8 mentions for Artiva Biotherapeutics and 2 mentions for Citius Oncology. Artiva Biotherapeutics' average media sentiment score of 1.44 beat Citius Oncology's score of 0.37 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artiva Biotherapeutics	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Citius Oncology and Artiva Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Citius Oncology compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Citius Oncology (NASDAQ:CTOR) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 9.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Inhibikase Therapeutics presently has a consensus target price of $5.40, indicating a potential upside of 171.36%. Citius Oncology has a consensus target price of $6.00, indicating a potential upside of 781.83%. Given Citius Oncology's higher possible upside, analysts clearly believe Citius Oncology is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Inhibikase Therapeutics and Inhibikase Therapeutics both had 2 articles in the media. Citius Oncology's average media sentiment score of 0.37 beat Inhibikase Therapeutics' score of 0.30 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Citius Oncology has lower revenue, but higher earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,010.54	-$48.26M	-$0.43	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Inhibikase Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.47, suggesting that its stock price is 247% more volatile than the broader market.

Inhibikase Therapeutics' return on equity of -41.31% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Citius Oncology	N/A	-99.47%	-42.16%

Summary

Inhibikase Therapeutics and Citius Oncology tied by winning 7 of the 14 factors compared between the two stocks.

How does Citius Oncology compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

31.5% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by company insiders. Comparatively, 9.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 2 articles in the media. Citius Oncology's average media sentiment score of 0.37 beat Anavex Life Sciences' score of 0.34 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anavex Life Sciences has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.47, meaning that its stock price is 247% more volatile than the broader market.

Anavex Life Sciences' return on equity of -38.76% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Citius Oncology	N/A	-99.47%	-42.16%

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Anavex Life Sciences currently has a consensus target price of $21.33, suggesting a potential upside of 672.95%. Citius Oncology has a consensus target price of $6.00, suggesting a potential upside of 781.83%. Given Citius Oncology's higher possible upside, analysts clearly believe Citius Oncology is more favorable than Anavex Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Anavex Life Sciences and Citius Oncology tied by winning 6 of the 12 factors compared between the two stocks.

How does Citius Oncology compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Citius Oncology has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
Citius Oncology	N/A	-99.47%	-42.16%

Citius Oncology has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	10.07	-$74.28M	-$1.16	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Foghorn Therapeutics currently has a consensus price target of $11.43, indicating a potential upside of 115.63%. Citius Oncology has a consensus price target of $6.00, indicating a potential upside of 781.83%. Given Citius Oncology's higher possible upside, analysts clearly believe Citius Oncology is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 9.8% of Citius Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Foghorn Therapeutics and Foghorn Therapeutics both had 2 articles in the media. Citius Oncology's average media sentiment score of 0.37 beat Foghorn Therapeutics' score of 0.33 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Foghorn Therapeutics has a beta of 2.86, meaning that its stock price is 186% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.47, meaning that its stock price is 247% more volatile than the broader market.

Summary

Citius Oncology beats Foghorn Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Citius Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTOR vs. The Competition

Export

Metric	Citius Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$63.26M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.45	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.46
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	1.26	8.66	10.96	6.46
Net Income	-$24.76M	$23.81M	$3.57B	$337.01M
7 Day Performance	8.69%	3.39%	2.12%	1.69%
1 Month Performance	-12.77%	10.81%	5.25%	3.81%
1 Year Performance	-87.21%	62.61%	33.29%	23.90%

Citius Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTOR Citius Oncology	2.3577 of 5 stars	$0.68 flat	$6.00 +781.8%	-87.2%	$63.26M	N/A	N/A	N/A	Positive News Analyst Upgrade Gap Up
ACIU AC Immune	3.1887 of 5 stars	$2.47 +0.6%	$7.50 +204.3%	+21.8%	$250.86M	$4.31M	N/A	140	News Coverage Analyst Forecast Gap Down
ARTV Artiva Biotherapeutics	4.1973 of 5 stars	$10.10 +3.1%	$39.00 +286.1%	+484.2%	$249.70M	$250K	N/A	81
IKT Inhibikase Therapeutics	2.1789 of 5 stars	$1.90 +1.3%	$5.40 +185.0%	N/A	$245.85M	N/A	N/A	6	News Coverage Gap Down
AVXL Anavex Life Sciences	1.9007 of 5 stars	$2.61 +1.2%	$21.33 +716.7%	-74.3%	$242.80M	N/A	N/A	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTOR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Oncology (CTOR) Competitors

CTOR vs. ACIU, ARTV, IKT, AVXL, and FHTX

How does Citius Oncology compare to AC Immune?

Summary

How does Citius Oncology compare to Artiva Biotherapeutics?

Summary

How does Citius Oncology compare to Inhibikase Therapeutics?

Summary

How does Citius Oncology compare to Anavex Life Sciences?

Summary

How does Citius Oncology compare to Foghorn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Oncology (CTOR) Competitors

CTOR vs. ACIU, ARTV, IKT, AVXL, and FHTX

How does Citius Oncology compare to AC Immune?

Which has higher earnings and valuation, CTOR or ACIU?

Do institutionals & insiders have more ownership in CTOR or ACIU?

Do analysts prefer CTOR or ACIU?

Which has more risk & volatility, CTOR or ACIU?

Does the media prefer CTOR or ACIU?

Is CTOR or ACIU more profitable?

Summary

How does Citius Oncology compare to Artiva Biotherapeutics?

Which has more volatility & risk, CTOR or ARTV?

Which has higher valuation and earnings, CTOR or ARTV?

Is CTOR or ARTV more profitable?

Do institutionals & insiders believe in CTOR or ARTV?

Do analysts prefer CTOR or ARTV?

Does the media prefer CTOR or ARTV?

Summary

How does Citius Oncology compare to Inhibikase Therapeutics?

Do institutionals & insiders believe in IKT or CTOR?

Do analysts recommend IKT or CTOR?

Does the media favor IKT or CTOR?

Which has preferable earnings and valuation, IKT or CTOR?

Which has more risk and volatility, IKT or CTOR?

Is IKT or CTOR more profitable?

Summary

How does Citius Oncology compare to Anavex Life Sciences?

Do institutionals and insiders have more ownership in AVXL or CTOR?

Does the media favor AVXL or CTOR?

Which has more risk & volatility, AVXL or CTOR?

Is AVXL or CTOR more profitable?

Which has stronger earnings and valuation, AVXL or CTOR?

Do analysts recommend AVXL or CTOR?

Summary

How does Citius Oncology compare to Foghorn Therapeutics?

Is FHTX or CTOR more profitable?

Which has better valuation & earnings, FHTX or CTOR?

Do analysts rate FHTX or CTOR?

Do institutionals & insiders have more ownership in FHTX or CTOR?

Does the media favor FHTX or CTOR?

Which has more volatility and risk, FHTX or CTOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools